Skip to main content

Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry.

Portier BP, Wang Z, Downs-Kelly E, Rowe JJ, Patil D, Lanigan C, Budd GT, Hicks DG, Rimm DL, Tubbs RR

Publication: Mod Pathol (2013) • Vol 26 • Page 1-9PMID: 22899285View on PubMed

Purpose

The purpose of this paper was to determine the effects of cold ischemia on the detection of ERBB2, also known as human epidermal growth factor receptor 2 (Her2), by immunohistochemistry (IHC) and by two methods of in situ hybridization (ISH) in breast cancer tissue. The effects of using different in situ hybridization scoring criteria were also investigated.

Conclusion

Generally, there was agreement in ERBB2 amplification status between fluorescence in situ hybridization (FISH) and dual color ISH, but differences between scoring methods were noted. ERBB2 IHC showed the highest concordance with FISH and dual color ISH results when the single probe scoring criteria was used. Importantly, dual color ISH generated a stronger signal intensity than FISH for both ERBB2 and CEP17 (chromosome 17), regardless of cold ischemia time. Cold ischemia times of >3 h significantly decreased the FISH signal intensities for ERBB2 in stroma and chromosome 17 in stroma and tumor compared to intensities after <1 h cold ischemia time.

Studies (1)

Purpose

The purpose of this study was to determine the effects of cold ischemia on the detection of ERBB2, also known as Her2, by IHC and by two methods of ISH (PathVysion FISH and the INFORM Her2 dual in situ DNA probe assay) in breast cancer tissue. The effects of using different ISH scoring criteria were also investigated. A total of 84 breast carcinoma specimens were used in this study, and IHC and ISH assays were performed using a tissue microarray.

Summary of Findings

For all cold ischemia times, FISH and dual color ISH were able to detect ERBB2 amplification with 100% concordance when either the ASCO/CAP dual probe or the FDA package insert scoring methods were employed. When the ASCO/CAP single probe scoring criteria was used, FISH and dual color ISH results generally still agreed, but amplification status of 3 of the 9 amplified cases changed to equivocal or non-amplified. These 3 cases all had a cold ischemia time of <1 h. ERBB2 IHC showed the highest concordance with FISH and dual color ISH results when the single probe scoring criteria was used. Other minor discrepancies among the scoring methods and between FISH, dual color ISH, and IHC were observed, the most common being an equivocal score for IHC while FISH and dual color ISH determined a non-amplified status, regardless of scoring method. Importantly, while dual color ISH generated a stronger signal intensity than FISH for both ERBB2 and CEP17, regardless of cold ischemia time (p<0.05, all), cold ischemia times of up to 3 h did not significantly decrease signal intensities for either assay. Cold ischemia times of >3 h did however significantly decrease the FISH signal intensities for ERBB2 in stroma and chromosome 17 in stroma and tumor compared to intensities after <1 h cold ischemia time (p<0.05, all).

  • Biospecimens

    TissueBreast
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    ProteinTissue microarray
    ProteinImmunohistochemistry
    DNAFISH
    DNAIn situ hybridization
    DNATissue microarray
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen AcquisitionCold ischemia time
    1-2 h
    2-3 h
    <1 h
    >3 h
    In situ hybridization SpecificData handling
    ASCO/CAP dual-probe scoring
    ASCO/CAP single-probe scoring
    FDA in-situ hybridization package insert
    In situ hybridization SpecificDetection method
    Dual color
    Fluorescence
    In situ hybridization SpecificTargeted nucleic acid
    CEP17
    ERBB2 (HER2)
    FISH SpecificData handling
    ASCO/CAP dual-probe scoring
    ASCO/CAP single-probe scoring
    FDA in-situ hybridization package insert
    FISH SpecificTargeted nucleic acid
    CEP17
    ERBB2 (HER2)
    Immunohistochemistry SpecificTargeted peptide/protein
    ERBB2 (HER2)
    Immunohistochemistry SpecificTechnology platform
    Dual color in situ hybridization
    FISH